SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), developer of advanced diagnostic products, announced today that it has been issued six patents by the U.S. Patent and Trademark Office for inventions related to diabetes and Alzheimers disease and biomarkers.
U.S. Patent No. 7,052, 849, “Protein biopolymer markers predictive of insulin resistance,” U.S. Patent No. 7, 049,397, “Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons,” and U.S. Patent No. 7,087,435, “Biopolymer marker indicative of disease state having a molecular weight of 2735 daltons,” relate to the use of mass spectrometry and time-of-flight detection to identify various biomarkers such as those associated with metabolic Syndrome X and conditions linked to Syndrome X. Early stages of Syndrome X are characterized by insulin resistance, abnormal blood lipids and high blood pressure; later stages lead to overt diabetes, kidney failure and heart failure.
In addition, U.S. Patent No. 7,026,129 “IG lambda biopolymer markers predictive of Alzheimers disease,” and U.S. Patent No. 7,074,576, “Protein biopolymer markers indicative of Alzheimers disease,” relate to the utilization of mass spectrometry and time-of-flight detection measures to elucidate biopolymer markers associated with Alzheimers disease and Syndrome X.
U.S. Patent No. 7,070,945, “Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment,” claims a method for determining those patients suffering from mild cognitive impairment who have a likelihood of progressing to Alzheimers disease. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, by immunoassay of bodily fluids. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.
For information about licensing opportunities, contact Nanogen.
About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company’s products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen’s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption “Factors That May Affect Results” and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Source: Nanogen, Inc.
